Program
Ivermectin
Also written as “ivermectin”, “Ivermectin cream” and “CD5024”.
Its studies are mostly in Rosacea · COVID-19 · Lice Infestations · Dermatitis, Atopic · Acne Vulgaris, led by 14 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Galderma Group | 60 open or running | phase 4since Nov 24, 2015 | Dec 14, 2011 | none ahead |
| Johnson & Johnson | 40 open or running | phase 3since Jan 8, 2009 | Jan 8, 2009 | none ahead |
| Topaz Pharmaceuticals | 40 open or running | phase 3since Feb 8, 2010 | Oct 1, 2009 | none ahead |
| Humanis Saglık Anonim Sirketi | 20 open or running | phase 1since Sep 13, 2021 | Sep 13, 2021 | none ahead |
| MedinCell S.A | 20 open or running | phase 2since Mar 28, 2022 | Oct 26, 2020 | none ahead |
| Sun Pharmaceutical Industries | 20 open or running | phase 1since May 3, 2017 | May 3, 2017 | none ahead |
| Genuine Research Center, Egypt | 10 open or running | phase 1since Apr 18, 2021 | Apr 18, 2021 | none ahead |
| Infectopharm Arzneimittel | 10 open or running | phase 3since Sep 28, 2021 | Sep 28, 2021 | none ahead |
| Insud Pharma | 10 open or running | phase 3since Aug 8, 2023 | Aug 8, 2023 | none ahead |
| mayne-pharma-international-pty-ltd | 10 open or running | phase 3since Oct 30, 2017 | Oct 30, 2017 | none ahead |
| Padagis | 10 open or running | phase 3since Jun 6, 2016 | Jun 6, 2016 | none ahead |
| Teva Pharmaceutical Industries | 10 open or running | phase 3since Jul 19, 2016 | Jul 19, 2016 | none ahead |
| united-laboratories | 10 open or running | phase 2since Sep 14, 2017 | Sep 14, 2017 | none ahead |
| Zydus Lifesciences | 10 open or running | phase 3since Sep 25, 2019 | Sep 25, 2019 | none ahead |
Also a collaborator on its studies: eva-pharma and biorasi-llc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 14 studies since Jan 8, 2009.
- Nov 21, 2016Phase 2 study in Acne VulgarisGalderma Group · NCT03034460 · 70 enrolled · Canada, France, Germany
- May 3, 2017Sun Pharmaceutical Industries's first study: phase 1 study in Lice InfestationsNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT03257943 · 413 enrolled · United States
- Aug 11, 2017Phase 2 study in Dermatitis, AtopicGalderma Group · NCT03250624 · 63 enrolled · Canada
- Sep 14, 2017united-laboratories's first study: phase 2 study in Pediculosis CapitisNew to united-laboratoriesunited-laboratories · NCT03286101 · 120 enrolled · Philippines
- Oct 30, 2017mayne-pharma-international-pty-ltd's first study: phase 3 study in Head LiceNew to mayne-pharma-international-pty-ltdmayne-pharma-international-pty-ltd · NCT03337490 · 296 enrolled · United States
- Sep 25, 2019Zydus Lifesciences's first study: phase 3 study in Facial RosaceaNew to Zydus LifesciencesZydus Lifesciences · NCT04106726 · 525 enrolled · United States
- Oct 26, 2020MedinCell S.A's first study: phase 1 study in COVID-19New to MedinCell S.AMedinCell S.A · NCT04632706 · 24 enrolled · United Kingdom
- Apr 18, 2021Genuine Research Center, Egypt's first study: phase 1 study in HealthyNew to Genuine Research Center, EgyptGenuine Research Center, Egypt · NCT04854460 · 30 enrolled · Egypt
- Sep 13, 2021Humanis Saglık Anonim Sirketi's first study: phase 1 study in Anthelmintic AgentNew to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT05082753 · 50 enrolled · Jordan
- Sep 28, 2021Infectopharm Arzneimittel's first study: phase 3 study in COVID-19New to Infectopharm ArzneimittelInfectopharm Arzneimittel · NCT05060666 · 412 enrolled
- Mar 28, 2022Phase 2 study in COVID-19MedinCell S.A · NCT05305560 · 400 enrolled · Bulgaria
- Aug 8, 2023Insud Pharma's first study: phase 3 study in COVID-19New to Insud PharmaInsud Pharma · NCT05993143 · 249 enrolled · Spain
- Aug 14, 2024Phase 1 study in RosaceaHumanis Saglık Anonim Sirketi · NCT06557603 · 44 enrolled · India
- Aug 26, 2026Phase 1 study in RosaceaSun Pharmaceutical Industries · NCT07795567 · 865 enrolled · United States
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Glutamate-gated chloride channel modulator; Glutamate-gated chloride channel modulator”ChEMBL 37, by rule
Studies
All 28 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07795567Rosacea · United States | 1 | Completed | Sun Pharmaceutical Industries | Jun 24, 2026 | 865 |
| NCT06557603Rosacea · India | 1 | Completed | Humanis Saglık Anonim Sirketi | Jul 11, 2024 | 44 |
| NCT05993143COVID-19 · Spain | 3 | Terminated | Insud Pharma | Jul 21, 2021 | 249 |
| NCT05305560COVID-19 · Bulgaria | 2 | Completed | MedinCell S.A | Sep 15, 2022 | 400 |
| NCT05060666COVID-19 | 3 | UNKNOWN | Infectopharm Arzneimittel | Mar 2022 | 412 |
| NCT05082753Anthelmintic Agent · Jordan | 1 | Completed | Humanis Saglık Anonim Sirketi | Dec 21, 2020 | 50 |
| NCT04854460Healthy · Egypt | 1 | Completed | Genuine Research Center, Egypt | Feb 25, 2021 | 30 |
| NCT04632706COVID-19 · United Kingdom | 1 | Completed | MedinCell S.A | Mar 9, 2021 | 24 |
| NCT04106726Facial Rosacea · United States | 3 | Completed | Zydus Lifesciences | Aug 4, 2020 | 525 |
| NCT03337490Head Lice · United States | 3 | Completed | mayne-pharma-international-pty-ltd | Dec 4, 2017 | 296 |
| NCT03286101Pediculosis Capitis · Philippines | 2 | Completed | united-laboratories | Oct 12, 2017 | 120 |
| NCT03250624Dermatitis, Atopic · Canada | 2 | Completed | Galderma Group | Jun 26, 2017 | 63 |
| NCT03257943Lice Infestations · United States | 1 | Completed | Sun Pharmaceutical Industries | Jun 27, 2017 | 413 |
| NCT03034460Acne Vulgaris · Canada, France, Germany | 2 | Completed | Galderma Group | Nov 2, 2016 | 70 |
| NCT02840461Moderate to Severe Papulopustular Rosacea · United States | 3 | Completed | Teva Pharmaceutical Industries | Nov 2016 | 630 |
| NCT02795117Rosacea | 3 | Completed | Padagis | Feb 2017 | 486 |
| NCT02616250Rosacea · United States, Canada | 4 | Completed | Galderma Group | Sep 2016 | 190 |
| NCT01493947Rosacea · Bulgaria, Czech Republic, France and more | 3 | Completed | Galderma Group | Dec 2013 | 962 |
| NCT01494467Rosacea · United States, Canada | 3 | Completed | Galderma Group | Aug 2013 | 688 |
| NCT01493687Rosacea · United States, Canada | 3 | Completed | Galderma Group | Jul 2013 | 683 |
| NCT01068158Head Lice · United States | 3 | Completed | Topaz Pharmaceuticals | Jun 2010 | 371 |
| NCT01066585Head Lice · United States | 3 | Completed | Topaz Pharmaceuticals | Jun 2010 | 410 |
| NCT00994422Head Lice · United States | 2 | Completed | Topaz Pharmaceuticals | Dec 2009 | 264 |
| NCT00988533Head Lice · United States | 1 | Completed | Topaz Pharmaceuticals | Nov 2009 | 30 |
| NCT00921674Healthy | 1 | Completed | Johnson & Johnson | Apr 2005 | 24 |
| NCT00921219Healthy | 1 | Completed | Johnson & Johnson | Nov 2005 | 34 |
| NCT00921154Fasting · Ireland | 1 | Completed | Johnson & Johnson | May 2005 | 24 |
| NCT00819520Lice Infestations · France, Ireland, Israel and more | 3 | Completed | Johnson & Johnson | Sep 2004 | 812 |
How it is read
Names in the registry
- “Ivermectin”, 4 entries
- “ivermectin”, 4 entries
- “Ivermectin cream”, 2 entries
- “CD5024”, 2 entries
- “0.5% Ivermectin Cream”, 2 entries
Conditions, from the studies’ own filings
- Rosacea, 9 studies
- COVID-19, 4 studies
- Lice Infestations, 3 studies
- Dermatitis, Atopic, 1 study
- Acne Vulgaris, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.